Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
about
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.Ranolazine: A Contemporary ReviewUpdate on ranolazine in the management of angina.Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Emerging clinical role of ranolazine in the management of angina.Efficacy and safety of ranolazine in patients with chronic stable angina.Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease - a randomized controlled trial.Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation.Ranolazine in patients with coronary artery disease.Utility of ranolazine in chronic stable angina patients.Ranolazine: a new option in the management of chronic stable angina.A rare neurological complication of ranolazine.Pathophysiology of the cardiac late Na current and its potential as a drug target.Evaluating symptoms to improve quality of life in patients with chronic stable angina.Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.The Use of Ranolazine in the Management of Recurrent Atrial Fibrillation After Percutaneous Radiofrequency AblationRefractory atrial fibrillation effectively treated with ranolazine.New developments in atrial antiarrhythmic drug therapy.Ranolazine: an anti-anginal drug with further therapeutic potential.Emerging medical treatment for angina pectoris.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias.Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.Ranolazine: clinical applications and therapeutic basis.Ranolazine for the treatment of atrial fibrillation.Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.The Significance of the Late Na+ Current for Arrhythmia Induction and the Therapeutic Antiarrhythmic Potential of Ranolazine.Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update.Ranolazine for stable angina pectoris.Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.Antiarrhythmic properties of ranolazine--from bench to bedside.The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation.Advances in the Pharmacologic Management of Atrial Fibrillation.Heart failure in older adults: a conversation with Dr Michael Rich. Interview by Dr Ali Ahmed.Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?
P2860
Q24605881-5A053B46-4BAE-4AAE-B21F-7426B66BAE23Q26765421-2A5559F8-4EAA-4DD1-BCF0-226F28984EE2Q33831222-5CDA92DC-7D37-4BF8-A9EF-463B99C7BA44Q33916951-D4EA759A-07C7-425F-A30B-419BD56D5B18Q34181734-BCB6F84A-CA8F-40E2-8E00-E2001B4CC3BDQ34235939-2AE78F0F-D104-4997-B54E-F6886B680666Q34383219-FDF551E2-9A88-4DB8-8BDD-32A3FE99FF49Q35091243-71EC36D9-4CF9-4B16-9310-C04CCA4142FEQ35139678-03933D8C-FE01-4B35-A137-E12417B93D64Q35650683-A3380616-27AD-49CB-AA1B-F62C46D8B302Q36258672-2B3CF2F1-9938-4506-B7E5-316A9BCA672FQ36534150-611CEE14-BED8-4B40-88AF-5F31D7D95A19Q36916931-1E43D23E-6540-45D1-B438-684C2236CBC0Q37004023-E82390FC-C564-4814-B3E8-4D8B1E7415FAQ37015957-5295862F-F4E5-4FBA-91B3-B6CAF62E3B21Q37018984-723EC1FD-D047-4150-83FB-76B8DFAE380EQ37276416-61AE3FF4-AD4C-4DE3-87FF-6FDB46CCCFC2Q37449790-453FF50A-A220-4309-B469-F0A5A6073A0EQ37495337-AD17201B-878D-438C-B1AF-75AC1E44EF28Q37496011-B93BB663-25FB-44B4-87A9-316BA925C78CQ37624444-DD4ED3AC-9E98-4A34-8D13-DADFD3BA2E25Q37697498-F72C5D53-86AC-4B42-9F95-9B5229659BA1Q37707393-0B398D8A-56D4-4E57-90E5-B074387BA3A3Q37729183-0AE17DB7-4970-4D1B-8107-64C1DBB1D1DCQ37827882-857D210C-D4D4-4ED5-9E6C-E7AACDCF5FA3Q38071920-15B27F28-D3D1-4C42-84CE-51115A407B61Q38074900-3188F7E8-F779-4CDB-B661-2716439A029AQ38075519-C8454F7F-6505-4923-B58E-2E79DEEF0F31Q38420631-111D07C8-91C2-4B1C-ADED-49AC38BBF42FQ38732082-9FD971F9-4BF2-43E8-86B5-0CEA1E9BFB40Q38821307-915B7646-AAB8-4AA9-83C1-3EE80A2B00AEQ38920729-669A4978-0A31-4920-9003-AF7EF9AA5371Q38971758-70A5FF81-3235-46E5-A6D6-CA0A36173928Q39397055-FD361AAD-2BE6-4B4D-B5B8-6A72092B1BB1Q39564664-CBE24D53-3614-4456-B128-F26790597928Q41178190-A50F8B60-AD8F-4660-A302-4E9759BA8B9EQ42777572-C66C4027-34F3-4E8E-8C0D-7D372EC385BEQ48553866-3A21042D-C1EE-4B58-825A-76C9BDA46E58Q55080711-F458D1EE-272F-4A20-B7E7-27CD353371F6
P2860
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Long-term safety of a novel an ...... Open Label Experience (ROLE).
@ast
Long-term safety of a novel an ...... Open Label Experience (ROLE).
@en
Long-term safety of a novel an ...... nolazine Open Label Experience
@nl
type
label
Long-term safety of a novel an ...... Open Label Experience (ROLE).
@ast
Long-term safety of a novel an ...... Open Label Experience (ROLE).
@en
Long-term safety of a novel an ...... nolazine Open Label Experience
@nl
prefLabel
Long-term safety of a novel an ...... Open Label Experience (ROLE).
@ast
Long-term safety of a novel an ...... Open Label Experience (ROLE).
@en
Long-term safety of a novel an ...... nolazine Open Label Experience
@nl
P1476
Long-term safety of a novel an ...... e Open Label Experience (ROLE)
@en
P2093
Michael J Koren
Michael Sweeney
P304
P356
10.1016/J.JACC.2006.10.067
P407
P577
2007-02-26T00:00:00Z